Astrazeneca Pharmaceuticals Lp v. Food and Drug Administration
850 F. Supp. 2d 230
D.D.C.2012Background
- AstraZeneca holds NDAs for Seroquel and Seroquel XR and has marketed them without generic competition since approval.
- A pediatric exclusivity period expires March 26, 2012, creating pressure over potential final FDA approvals for generics.
- AstraZeneca seeks a three-year new patient population exclusivity tied to 2009 FDA supplemental NDAs and labeling changes, including data in Table 2.
- AstraZeneca filed two citizen petitions in Sept. 2011 asking FDA not to grant final approval to any generic that omits Table 2 data until after Dec. 2, 2012.
- FDA denied the petitions on March 7, 2012; AstraZeneca sued on March 12, 2012 seeking a preliminary injunction to block final approval of generics.
- The court denied the injunction, held the claim not ripe for review, and dismissed the case without prejudice.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Is AstraZeneca’s claim ripe for judicial review? | AstraZeneca argues the FDA’s pending actions affect exclusivity and labeling. | FDA contends no final agency action on the relevant ANDAs exists yet; ripe requires concrete agency action. | Not ripe; dismissal without prejudice. |
| Is AstraZeneca likely to succeed on the merits if ripe? | Claim hinges on new patient population exclusivity and exclusivity interaction with pending ANDAs. | Outcomes depend on future agency decisions; abstract, hypothetical issues not fit for review. | Not ripe; court declines to assess likelihood of success. |
| Do AstraZeneca’s alleged irreparable harm and public interest favor relief while unripe? | Immediate market protection prevents loss from upcoming generic entry. | Irreparable harm is speculative absent final agency action; public interests favor orderly FDA process. | Not weighed; lack of ripeness precludes injunctive relief. |
Key Cases Cited
- Abbott Labs. v. Gardner, 387 F.2d 136 (U.S. 1967) (ripeness doctrine and finality considerations for administrative review)
- Pfizer Inc. v. Shalala, 182 F.3d 975 (D.C. Cir. 1999) (finality and ripeness in petitions challenging agency action)
- Teva Pharm. USA, Inc. v. Sebelius, 595 F.3d 1303 (D.C. Cir. 2010) (premature judicial review when agency decisions depend on contingent future action)
- Mylan Pharm. v. U.S. Food & Drug Admin., 789 F. Supp. 2d 1 (D.D.C. 2011) (ripeness and premature challenge to FDA exclusivity decisions)
- Cephalon, Inc. v. Sebelius, 796 F. Supp. 2d 212 (D.D.C. 2011) (postponement of review pending concrete agency action supports ripeness)